Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT).

PLoS One 2015 10;10(12):e0143846. Epub 2015 Dec 10.

Institute for Ophthalmic Research, Center for Ophthalmology, University of Tübingen, Tübingen, Germany.

Unlabelled: Restoring vision in inherited retinal degenerations remains an unmet medical need. In mice exhibiting a genetically engineered block of the visual cycle, vision was recently successfully restored by oral administration of 9-cis-retinyl acetate (QLT091001). Safety and visual outcomes of a once-daily oral dose of 40 mg/m2/day QLT091001 for 7 consecutive days was investigated in an international, multi-center, open-label, proof-of-concept study in 18 patients with RPE65- or LRAT-related retinitis pigmentosa. Eight of 18 patients (44%) showed a ≥20% increase and 4 of 18 (22%) showed a ≥40% increase in functional retinal area determined from Goldmann visual fields; 12 (67%) and 5 (28%) of 18 patients showed a ≥5 and ≥10 ETDRS letter score increase of visual acuity, respectively, in one or both eyes at two or more visits within 2 months of treatment. In two patients who underwent fMRI, a significant positive response was measured to stimuli of medium contrast, moving, pattern targets in both left and right hemispheres of the occipital cortex. There were no serious adverse events. Treatment-related adverse events were transient and the most common included headache, photophobia, nausea, vomiting, and minor biochemical abnormalities. Measuring the outer segment length of the photoreceptor layer with high-definition optical coherence tomography was highly predictive of treatment responses with responders having a significantly larger baseline outer segment thickness (11.7 ± 4.8 μm, mean ± 95% CI) than non-responders (3.5 ± 1.2 μm). This structure-function relationship suggests that treatment with QLT091001 is more likely to be efficacious if there is sufficient photoreceptor integrity.

Trial Registration: ClinicalTrials.gov NCT01014052.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0143846PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687523PMC
July 2016
53 Reads

Publication Analysis

Top Keywords

adverse events
8
outer segment
8
proof-of-concept study
8
retinitis pigmentosa
8
letter score
4
determined goldmann
4
goldmann visual
4
visual fields
4
tomography highly
4
area determined
4
functional retinal
4
highly predictive
4
retinal area
4
coherence tomography
4
fields 67%
4
patients ≥5
4
≥5 ≥10
4
high-definition optical
4
optical coherence
4
28% patients
4

References

(Supplied by CrossRef)
Molecular genetics of human retinal disease
A Rattner et al.
Annu Rev Genet 1999
Epidemiology of retinitis pigmentosa in Denmark
M Haim et al.
Acta Ophthalmol Scand Suppl 2002
Retinitis pigmentosa
DT Hartong et al.
Lancet 2006
Retinitis pigmentosa
C Hamel et al.
Orphanet J Rare Dis 2006
Chemistry of the retinoid (visual) cycle
PD Kiser et al.
Chem Rev 2014

Similar Publications